TABLE 1

Treatment assignment and persistent bacteremia, univariable analyses

CharacteristicTreatment assignmentaBacteremia durationa
Combob (n = 90)VAN (n = 66)P value<5 days (n = 103)≥5 days (n = 53)P value
Age (yr, mean ± SD)58 ± 1661 ± 170.31758 ± 1660 ± 170.539
Male50 (55.6)35 (53.0)0.87157 (53.3)28 (52.8)0.865
Race/ethnicity0.4170.392
    Caucasian55 (61.1)36 (54.5)63 (61.2)28 (52.8)
    Other35 (38.9)30 (45.5)40 (38.8)25 (47.2)
Diabetes mellitus43 (47.8)27 (40.9)0.41945 (43.7)25 (47.2)0.735
Cancer16 (17.8)15 (22.7)0.54318 (17.5)13 (24.5)0.299
Lung disease20 (22.2)10 (15.2)0.30917 (16.5)13 (24.5)0.284
Congestive heart failure14 (15.6)8 (12.1)0.64416 (15.5)6 (11.3)0.628
End-stage renal disease27 (30.0)20 (30.3)>0.99932 (31.1)15 (28.3)0.854
Hemodialysis15 (16.7)15 (22.7)0.41219 (18.5)11 (20.8)0.831
PITT bacteremia score ≥419 (12.2)12 (18.8)0.69023 (22.1)8 (15.4)0.397
Intensive care unit admission41 (45.6)22 (33.3)0.14043 (41.8)20 (37.7)0.731
Bacteremia source0.1670.156
    Primary endovascular27 (30.0)24 (36.4)32 (31.1)19 (35.9)
    Secondary50 (55.6)27 (40.9)56 (54.4)21 (39.6)
    Catheter related13 (14.4)15 (22.7)15 (15.0)13 (24.5)
Prosthesis14 (15.6)18 (27.3)0.10720 (19.4)12 (22.6)0.678
VAN MIC ≤1 mg/liter74 (82.2)57 (86.4)0.51784 (81.6)47 (88.6)0.357
Initial VAN level (mg/liter; median [IQR])17.8 (14.0–23.4)15.7 (11.3–20.2)0.04117.5 (14.0–23.0)15.0 (11.1–23.2)0.108
VAN therapy duration (days [range])12 (8–26)11.5 (7–22)0.77312 (7–31)13 (9–19)0.990
Persistent bacteremia24 (26.7)29 (43.9)0.027
In-hospital mortality14 (15.6)9 (13.6)0.82214 (13.6)9 (17.0)0.636
Acute kidney injury17 (18.9)5 (7.6)0.06213 (12.6)9 (17.0)0.474
  • a Data presented as n (%) unless noted otherwise.

  • b Piperacillin-tazobactam (60.0%), cefepime (15.6%), ceftriaxone (12.2%), meropenem (4.4%), imipenem-cilastatin (3.3%), ampicillin-sulbactam (2.2%), cefazolin (1.1%), and doripenem (1.1%).